<?xml version="1.0" encoding="UTF-8"?>
<p id="Par72">Neutralizing antibodies against nCoV 19 surface antigens block virus entry, of which S protein considered a good candidate. These monoclonal neutralizing antibodies provide passive immunity in the time of exposure like palivizumab as a putative model that has been applied for the prevention of RSV infection. Anti-inflammatory antibodies like anti IL6 receptor (Tocilizumab) and anti ITGA4 (Natalizumab) may repress inflammation and cellular extravasation [
 <xref ref-type="bibr" rid="CR78">78</xref>].
</p>
